Business Wire

ACHILLES-VACCINES

25.1.2021 12:39:04 CET | Business Wire | Press release

Share
AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2

Today, AchilleS Vaccines, a biotech company based in Siena (Italy), announced the successful industrial development of a novel monoclonal antibody (mAb) to treat COVID-19. The treatment, patented by Prof Rino Rappuoli’s MAD Lab and developed by AchilleS, could greatly improve access to COVID-19 treatment and has several advantages compared to conventional mAbs: it can be administered intramuscularly, avoiding the risks of hospitalization. Additionally, this mAb is highly potent and the low dosage treatment offers significant health and cost benefits.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005376/en/

The AchilleS antibody project ‘mAbCo19’ will now be further tested in the clinic, possibly leading to an emergency market authorization this summer. AchilleS is developing this new therapeutic in cooperation with Toscana Life Sciences (TLS) and several partners, such as ExcelGene, Menarini Biotech and IBI Lorenzini.

"This event, for a small company like ours, is really something to be proud of." says Riccardo Baccheschi, CEO of AchilleS. “By continuing to play our role as an enthusiastic contributor to this potentially market-shaping compound, we will further support and materially coordinate the TLS-sponsored clinical and regulatory processes, hopefully up to market licensing. We hope to actively contribute to the elimination of this pandemic in Europe and in the world and to the return to a normal life for all of us, our collaborators and our loved ones ".

Rino Rappuoli, Director of MAD Lab TLS and inventor of the mAb said: “We are very happy to see that our monoclonal continues to perform extremely well not only against the wild type virus but also against the emerging variants.”

In June 2020 AchilleS received a substantial investment from the EU Malaria Fund (EUMF) to develop vaccines for malaria, other infectious diseases, as well as for the ‘mAbCo19’ project. The EUMF is a public-private partnership providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally.

“The development of this treatment against COVID-19 is very timely and much needed.” says Holm Keller, Executive Chairman of kENUP Foundation. “It shows that small- and medium-sized companies play an important role in the fight against COVID-19 and Malaria. We are grateful for the important work of AchilleS, TLS and Menarini.”

More information can be found at https://www.achillesvaccines.com and https://www.covidx.eu/mabco19 .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PIF Delivers Strong Revenue and Profit Growth in 202517.8.2026 13:54:00 CEST | Press release

Revenue rose 9% to $120 billion while net profit more than doubled to $17 billionCumulative domestic investments reached more than $199 billion since 2021PIF has contributed more than $342 billion to Saudi Arabia’s real non-oil GDP between 2021 and 2025Assets under management exceed $900 billion, up from around $530 in 2021 and $150 billion in 2015 PIF today published its 2025 Annual Report demonstrating strong financial performance and continued progress against its long-term objectives. As a long-term investor with a unique mandate to drive the economic transformation of Saudi Arabia and deliver sustainable financial returns, PIF maintained a diversified portfolio in 2025, balancing returns with national impact and long-term resilience. Maintaining Financial Discipline In 2025, revenue rose 9% year on year to $120 billion, while net profit more than doubled to $17 billion, supported by stronger contributions from maturing portfolio companies. PIF retained over $900 billion in assets

Foundever Successfully Closes a Holistic Recapitalization, Reducing its Debt by Nearly $900 Million and Strengthening its Financial Position for Long-Term Growth17.8.2026 13:30:00 CEST | Press release

Secures $225 Million Equity Infusion; Revolving Credit Facility and Term Loan Maturities ExtendedBenoit Leclercq Appointed Interim Chief Executive Officer to Lead Foundever Through its Next Phase of Growth; Company Begins Formal Search Process for Permanent CEO Foundever Group S.A.® (“Foundever” or the “Company”) – a global leader in integrated customer experience, digital operations and analytics services, today announced that it has successfully closed a holistic recapitalization (the “Transaction”) in coordination with 95.4% of the lenders under its term loan facility (“Term Loan Lenders”), 100% of its revolving credit facility lenders (“RCF Lenders”), and the Company’s existing majority shareholders. The Transaction meaningfully strengthens Foundever’s financial foundation and positions the Company to invest in its growth strategy. Key terms of the Transaction include: Company's existing majority shareholders invest $225 million into common equity. Term loan facility exchange reduc

Uniphore Launches Marketing AI as Marketing Moves Beyond the CDP17.8.2026 13:30:00 CEST | Press release

Digital Twins and custom Small Language Models enable brands to know every customer better, simulate outcomes before spending and predict what’s next Uniphore, the Business AI company, today launched Marketing AI, ushering in a new era of enterprise marketing built on customer intelligence rather than customer data management. Uniphore Marketing AI gives marketers the ability to know every customer better than ever before, predict what each customer is likely to do next and simulate marketing outcomes before committing budget. The system continuously learns from every customer interaction, making its predictions more accurate with every cycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817325069/en/ The Uniphore Marketing AI Flywheel: A Self-Learning System Named a Leader in the 2026 Gartner® Magic Quadrant™ for Customer Data Platforms, Uniphore has helped enterprises bring customer data together while providing sover

Instabase Becomes SuperApp, Launches the AI Collaboration Super App17.8.2026 12:00:00 CEST | Press release

AI was single-player. SuperApp makes it multiplayer Your whole team and leading AI models from Anthropic, OpenAI, Google, xAI, and others think, debate, and create together in one live thread — from the first idea to the final deliverable. Available today. SuperApp, Inc., formerly Instabase, Inc., today launched SuperApp, the AI collaboration super app, available on the web, iOS, Android, and desktop. SuperApp brings teams and leading AI models from Anthropic, OpenAI, Google, xAI, and others into one live thread — from the first conversation to finished work. The company changed its name to reflect the new product and company direction. Work today is split into three. Teams talk in one app. They ask AI in another. They make the final work somewhere else. Every handoff asks people to remember what the software forgot. SuperApp brings those moments together. People and AI begin in the same live thread. Teams can use Claude from Anthropic, GPT from OpenAI, Gemini from Google, Grok from xA

Confluence Launches Confluence POINT, Bringing AI-Enabled Automation Across Its Product Suite.17.8.2026 11:04:00 CEST | Press release

Document validation and intelligence and the Revolution conversational interface are live today; the first in a wave of AI capabilities running within and alongside Confluence’s solutions. Confluence Technologies, Inc. (“Confluence”), a global leader in regulatory, analytics, and investor communications solutions for the investment management industry, today announced the launch of Confluence POINT, AI-enabled automation that optimizes workflows across its solutions. Confluence delivers specialist regulatory, analytics and investor solutions that are unrivalled at what they do. POINT is AI-enabled automation that runs within and alongside these solutions, letting them do more for our clients, reducing manual effort that typically occurs before or after automated processes. POINT Validation transforms and validates documents across a range of formats, including unstructured data. POINT’s AI-powered validation is complete in minutes, delivered via an automated checklist that runs indepen

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye